Arcturus, JNJ to develop nucleic acids to treat HBV
Arcturus Therapeutics Inc. (San Diego, Calif.) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize nucleic acid-based compounds to treat HBV. The companies will use Arcturus' unlocked nucleomonomer agent (UNA) Oligomer chemistry and LUNAR lipid-mediated delivery platform. The deal includes an option to expand into other infectious and respiratory diseases.
Arcturus will receive an undisclosed upfront cash payment and R&D support, and will be eligible for preclinical, developmental and sales milestone payments, as well as royalties. Janssen will assume responsibility for development costs and all commercialization costs associated with the program...
BCIQ Company Profiles